Skip To Main Content
Nathan Pennell on Muck Rack

Nathan Pennell

As seen in: Nature, Wiley, Wiley Online Library, The Oncologist, U.S. News and World Report, JAMA Oncology, Healio, HemOnc Today, Journal of Clinical Oncology, Chest and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Nathan

Contact Nathan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST

|
By Maurice Pérol, Nathan Pennell, Geoffrey Liu
| Journal of Clinical Oncology Verified
ROS1) gene fusions, first reported in 2007,1,2 are oncogenic molecular alterations resulting in constitutive activation of the ROS1 kinase domain and drive persistent downstream signaling and dysregulated cell differentiation, proliferation, and survival.
Open in Who Shared Issue with article?

Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST

|
By Maurice Pérol, Nathan Pennell, Geoffrey Liu
| brnw.ch
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.
Open in Who Shared Issue with article?

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors - Nature

|
By Ferdinandos Skoulidis, Ana Cobo Verified, Meagan Montesion, Yi Yu, Natalie I. Vokes, Joseph Murray, Justin F. Gainor, Catherine Shu, Collin M Blakely, Chad V. Pecot, Fabrizio Tabbò, Matthias Scheffler, Meghan J. Mooradian, Kurt A. Schalper, Valsamo Anagnostou, Patrick M. Forde, Amy Cummings, Jonathan Goldman, Sharyn I. Katz, Ying Ni, Ludovic Lacroix, Yasir Y. Elamin, Marcelo V. Negrao, Vincent Lam, Whitney Lewis, Jack A. Roth, Stephen Swisher, Richard Lee, Teng Zhou, Jianjun Zhang, Lauren A Byers, don gibbons, J. Lee, Trever G. Bivona, Edward B. Garon, Naiyer A. Rizvi, Giorgio Vittorio Scagliotti, Benjamin Besse, Roy S. Herbst, Heather Wakelee, Nathan Pennell, Pasi A. Jänne, David P. Carbone, Charles M. Rudin, Lee A. Albacker, Solange Peters, Melissa Johnson, Kwok Wong, Monte M. Winslow, Tina Cascone
| Nature Verified
Abstract For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of anti-tumour activity and immune-related toxicities, when compared with treatment with PD-(L)1 inhibitors alone. However, there are currently no validated biomarkers to identify which patients will benefit from dual ICB1,2.
Open in Who Shared Issue with article?
See all 59 licensed articles (69 Total)